Cargando…

CSF p-tau as a potential cognition impairment biomarker in ALS

BACKGROUND: Cerebrospinal fluid (CSF) and serum tau (t-tau, p-tau) are potential biomarkers for neurodegeneration in Alzheimer disease (AD), but their role in amyotrophic lateral sclerosis (ALS) is unclear. OBJECTIVES: The aim of our study was to evaluate CSF and serum p-tau and t-tau in patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gong, Zhongying, Gao, Lina, Lu, Yi, Wang, Zhiyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663818/ https://www.ncbi.nlm.nih.gov/pubmed/36388201 http://dx.doi.org/10.3389/fneur.2022.991143

Ejemplares similares

CSF tau and β-amyloid as biomarkers for mild cognitive impairment
por: Hampel, Harald, et al.
Publicado: (2004)

Biomarker Supervised G-CSF (Filgrastim) Response in ALS Patients
por: Johannesen, Siw, et al.
Publicado: (2018)

Serum Neuroglobin as a Potential Prognostic Biomarker for Cognitive Impairment After Intracerebral Hemorrhage
por: Gao, Yu, et al.
Publicado: (2022)

The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial
por: Abdullah, Laila, et al.
Publicado: (2020)

CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals
por: Simrén, Joel, et al.
Publicado: (2022)

Alterations in Tau Metabolism in ALS and ALS-FTSD
por: Strong, Michael J., et al.
Publicado: (2020)

Gut Microbiota and Targeted Biomarkers Analysis in Patients With Cognitive Impairment
por: Lu, Shourong, et al.
Publicado: (2022)

CSF P-tau 231 as Biomarker in Alzheimer's Disease
por: Mukherjee, Adreesh, et al.
Publicado: (2022)

Plasma Amyloid Beta and Tau Levels Are Predictors of Post-stroke Cognitive Impairment: A Longitudinal Study
por: Chi, Nai-Fang, et al.
Publicado: (2019)

CSF Neurofilament Light Chain Elevation Predicts ALS Severity and Progression
por: Sun, Qionghua, et al.
Publicado: (2020)

CSF and Serum Biomarkers of Cerebral Damage in Autoimmune Epilepsy
por: Nass, Robert Daniel, et al.
Publicado: (2021)

Tau and Amyloid-β Peptides in Serum of Patients With Parkinson's Disease: Correlations With CSF Levels and Clinical Parameters
por: Schirinzi, Tommaso, et al.
Publicado: (2022)

CSF oligoclonal IgG bands are not associated with ALS progression and prognosis
por: Klose, Veronika, et al.
Publicado: (2023)

Amyloid-β, Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data
por: Bos, Isabelle, et al.
Publicado: (2018)

Editorial: Cognitive and Behavioral Features in ALS: Beyond Motor Impairment in ALS-FTD Spectrum Disorders
por: Bersano, Enrica, et al.
Publicado: (2022)

(18)F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

CSF sTREM2 in delirium—relation to Alzheimer’s disease CSF biomarkers Aβ42, t-tau and p-tau
por: Henjum, Kristi, et al.
Publicado: (2018)

Editorial: CSF and blood biomarkers in COVID-19 and other neuroinfectious diseases
por: Foschi, Matteo, et al.
Publicado: (2023)

CSF biomarkers for early-onset Alzheimer's disease in Chinese population from PUMCH dementia cohort
por: Lei, Dan, et al.
Publicado: (2023)

Relationship between glycemic control and cognitive impairment: A systematic review and meta-analysis
por: Lin, Yufeng, et al.
Publicado: (2023)

CSF p-tau231: A biomarker for early preclinical Alzheimer?
por: Suárez-Calvet, Marc
Publicado: (2022)

Quantitative (18)F-AV1451 Brain Tau PET Imaging in Cognitively Normal Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease Patients
por: Zhao, Qian, et al.
Publicado: (2019)

Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease
por: Fossati, Silvia, et al.
Publicado: (2019)

Plasma biomarkers for diagnosis of Alzheimer's disease and prediction of cognitive decline in individuals with mild cognitive impairment
por: Kivisäkk, Pia, et al.
Publicado: (2023)

Incremental Value of CSF Biomarkers in Clinically Diagnosed AD and Non-AD Dementia
por: Oudart, Jean-Baptiste, et al.
Publicado: (2020)

PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers
por: Vasilevskaya, Anna, et al.
Publicado: (2020)

Increased CSF levels of total Tau in patients with subcortical cerebrovascular pathology and cognitive impairment
por: Radanovic, Márcia, et al.
Publicado: (2017)

Tau Pathology in Parkinson's Disease
por: Zhang, Xue, et al.
Publicado: (2018)

The P300 Event-Related Potential Component and Cognitive Impairment in Epilepsy: A Systematic Review and Meta-analysis
por: Zhong, Rui, et al.
Publicado: (2019)

Molecular imaging biomarkers in familial frontotemporal lobar degeneration: Progress and prospects
por: Wang, Ruihan, et al.
Publicado: (2022)

Bibliometric review of 1992–2022 publications on acupuncture for cognitive impairment
por: Zhou, Runjin, et al.
Publicado: (2022)

Glycan biomarkers for Alzheimer disease correlate with T‐tau and P‐tau in cerebrospinal fluid in subjective cognitive impairment
por: Schedin‐Weiss, Sophia, et al.
Publicado: (2020)

Screening for Cognitive Impairment After Stroke: Validation of the Chinese Version of the Quick Mild Cognitive Impairment Screen
por: Xu, Yangfan, et al.
Publicado: (2021)

Shared CSF Biomarker Profile in Idiopathic Normal Pressure Hydrocephalus and Subcortical Small Vessel Disease
por: Jeppsson, Anna, et al.
Publicado: (2022)

Serum Irisin as a Potential Biomarker for Cognitive Decline in Vascular Dementia
por: Zhang, Feng, et al.
Publicado: (2021)

MRI-Visible Perivascular Spaces Associated With Cognitive Impairment in Military Veterans With Traumatic Brain Injury Mediated by CSF P-Tau
por: Wang, Ming-Liang, et al.
Publicado: (2022)

The Application of rs-fMRI in Vascular Cognitive Impairment
por: Wang, Ran, et al.
Publicado: (2020)

Association Analysis of Peripheral and CSF Biomarkers in Late Mild Cognitive Impairment
por: Zhang, Tao, et al.
Publicado: (2020)

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
por: Ossenkoppele, Rik, et al.
Publicado: (2021)

Risk factors for predicting progression from normal cognition to mild cognitive impairment: protocol for a systematic review and meta-analysis of cohort studies
por: Wang, Jie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9h3e4dsnema5vdph8qnrs1v157